rs149194681
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PM1
The NM_024675.4(PALB2):āc.3320T>Cā(p.Leu1107Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000991 in 1,613,994 control chromosomes in the GnomAD database, with no homozygous occurrence. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense has been classified as Uncertain significance.
Frequency
Consequence
NM_024675.4 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary breast carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics
- Fanconi anemia complementation group NInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 3Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- familial ovarian cancerInheritance: AD Classification: MODERATE Submitted by: ClinGen
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PALB2 | NM_024675.4 | c.3320T>C | p.Leu1107Pro | missense_variant | Exon 12 of 13 | ENST00000261584.9 | NP_078951.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PALB2 | ENST00000261584.9 | c.3320T>C | p.Leu1107Pro | missense_variant | Exon 12 of 13 | 1 | NM_024675.4 | ENSP00000261584.4 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152194Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.00000795 AC: 2AN: 251476 AF XY: 0.00000736 show subpopulations
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1461800Hom.: 0 Cov.: 31 AF XY: 0.00000825 AC XY: 6AN XY: 727202 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152194Hom.: 0 Cov.: 31 AF XY: 0.0000134 AC XY: 1AN XY: 74350 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:3Benign:1
This missense variant replaces leucine with proline at codon 1107 of the PALB2 protein. Computational prediction suggests that this variant may not impact protein structure and function. A functional study has reported that this variant does not impact PALB2 function in a homology-directed repair assay (PMID: 31636395). This variant has been reported in individuals affected with breast cancer (PMID: 30303537, 33980423) and in a breast cancer case-control meta-analysis in 10/60466 cases and 3/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID PALB2_010666). This variant also has been detected with expected loss-of-function truncation variants in PALB2 or BRCA2 in individuals affected with PALB2/BRCA2-associated cancer (Color internal data). This variant has been identified in 3/282872 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
- -
- -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
not specified Uncertain:2
- -
DNA sequence analysis of the PALB2 gene demonstrated a sequence change, c.3320T>C, in exon 12 that results in an amino acid change, p.Leu1107Pro. This sequence change has been described in the gnomAD database with a frequency of 0.0023% in the non-Finnish European subpopulation (dbSNP rs149194681). This sequence change has been previously identified in individuals with a personal and/or family history of breast cancer (PMID: 30303537, 31159747). The p.Leu1107Pro change affects a moderately conserved amino acid residue located in a domain of the PALB2 protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Leu1107Pro substitution. An experimental study evaluating PALB2 function using a cellular homology directed DNA repair (HDR) assay demonstrated that this variant did not disrupt HDR to the same level as known pathogenic variants (PMID: 31636395). Due to insufficient evidences, the clinical significance of the p.Leu1107Pro change remains unknown at this time. -
not provided Uncertain:2
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Identified in individual(s) with breast cancer (PMID: 30303537); Published functional studies suggest no damaging effect: demonstrates homology directed repair (HDR) activity similar to wild type (PMID: 31636395); This variant is associated with the following publications: (PMID: 24123366, 31159747, 30303537, 31636395) -
- -
Familial cancer of breast Uncertain:2
- -
This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 1107 of the PALB2 protein (p.Leu1107Pro). This variant is present in population databases (rs149194681, gnomAD 0.002%). This missense change has been observed in individual(s) with breast cancer (PMID: 30303537, 33980423). ClinVar contains an entry for this variant (Variation ID: 142465). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The proline amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Experimental studies have shown that this missense change does not substantially affect PALB2 function (PMID: 31636395). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Breast-ovarian cancer, familial, susceptibility to, 5 Uncertain:1
This sequence change replaces leucine with proline at codon 1107 of the PALB2 protein (p.Leu1107Pro). This variant is present in population databases (rs149194681, ExAC 0.001%). This variant has been observed in an individual with breast cancer (PMID: 30303537). ClinVar contains an entry for this variant (Variation ID: 142465) with 6 submissions all of which describe it as of uncertain significance, 2 stars, no conflicts. In-silico predictions show benign computational verdict based on 11 benign predictions from BayesDel_addAF, DANN, DEOGEN2, EIGEN, FATHMM-MKL, LIST-S2, M-CAP, MVP, MutationAssessor, PrimateAI and SIFT vs 1 pathogenic prediction from MutationTaster and the position is not strongly conserved. These predictions have not been confirmed by published functional studies.Therefore, it has been classified as a Variant of Uncertain Significance. -
Fanconi anemia complementation group N;C3150547:Pancreatic cancer, susceptibility to, 3;C5830615:Breast-ovarian cancer, familial, susceptibility to, 5 Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at